415 related articles for article (PubMed ID: 33741010)
1. Coagulation phenotypes in sepsis and effects of recombinant human thrombomodulin: an analysis of three multicentre observational studies.
Kudo D; Goto T; Uchimido R; Hayakawa M; Yamakawa K; Abe T; Shiraishi A; Kushimoto S
Crit Care; 2021 Mar; 25(1):114. PubMed ID: 33741010
[TBL] [Abstract][Full Text] [Related]
2. Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy.
Levi M; Vincent JL; Tanaka K; Radford AH; Kayanoki T; Fineberg DA; Hoppensteadt D; Fareed J
Crit Care Med; 2020 Aug; 48(8):1140-1147. PubMed ID: 32697484
[TBL] [Abstract][Full Text] [Related]
3. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.
Hagiwara A; Tanaka N; Uemura T; Matsuda W; Kimura A
BMJ Open; 2016 Dec; 6(12):e012850. PubMed ID: 28039291
[TBL] [Abstract][Full Text] [Related]
4. Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan.
Yamakawa K; Umemura Y; Hayakawa M; Kudo D; Sanui M; Takahashi H; Yoshikawa Y; Hamasaki T; Fujimi S;
Crit Care; 2016 Jul; 20(1):229. PubMed ID: 27472991
[TBL] [Abstract][Full Text] [Related]
5. Markers of acute kidney injury in patients with sepsis: the role of soluble thrombomodulin.
Katayama S; Nunomiya S; Koyama K; Wada M; Koinuma T; Goto Y; Tonai K; Shima J
Crit Care; 2017 Aug; 21(1):229. PubMed ID: 28841902
[TBL] [Abstract][Full Text] [Related]
6. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
Yoshimura J; Yamakawa K; Ogura H; Umemura Y; Takahashi H; Morikawa M; Inoue Y; Fujimi S; Tanaka H; Hamasaki T; Shimazu T
Crit Care; 2015 Mar; 19(1):78. PubMed ID: 25883031
[TBL] [Abstract][Full Text] [Related]
7. Web-based application for predicting the potential target phenotype for recombinant human thrombomodulin therapy in patients with sepsis: analysis of three multicentre registries.
Goto T; Kudo D; Uchimido R; Hayakawa M; Yamakawa K; Abe T; Shiraishi A; Kushimoto S
Crit Care; 2022 May; 26(1):145. PubMed ID: 35590381
[TBL] [Abstract][Full Text] [Related]
8. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey.
Iba T; Nisio MD; Levy JH; Kitamura N; Thachil J
BMJ Open; 2017 Sep; 7(9):e017046. PubMed ID: 28963294
[TBL] [Abstract][Full Text] [Related]
9. Effect of Recombinant Human Soluble Thrombomodulin on Coagulation-Related Variables in Patients With Sepsis-Induced Disseminated Intravascular Coagulation: A Retrospective Observational Study.
Mitaka C; Kawagoe I; Satoh D; Hayashida M
Clin Appl Thromb Hemost; 2021; 27():10760296211050356. PubMed ID: 34859680
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.
Vincent JL; Ramesh MK; Ernest D; LaRosa SP; Pachl J; Aikawa N; Hoste E; Levy H; Hirman J; Levi M; Daga M; Kutsogiannis DJ; Crowther M; Bernard GR; Devriendt J; Puigserver JV; Blanzaco DU; Esmon CT; Parrillo JE; Guzzi L; Henderson SJ; Pothirat C; Mehta P; Fareed J; Talwar D; Tsuruta K; Gorelick KJ; Osawa Y; Kaul I
Crit Care Med; 2013 Sep; 41(9):2069-79. PubMed ID: 23979365
[TBL] [Abstract][Full Text] [Related]
11. Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin.
Hoppensteadt D; Tsuruta K; Cunanan J; Hirman J; Kaul I; Osawa Y; Fareed J
Clin Appl Thromb Hemost; 2014 Mar; 20(2):129-35. PubMed ID: 23804232
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study.
Hayakawa M; Yamakawa K; Saito S; Uchino S; Kudo D; Iizuka Y; Sanui M; Takimoto K; Mayumi T; Ono K;
Thromb Haemost; 2016 Jun; 115(6):1157-66. PubMed ID: 26939575
[TBL] [Abstract][Full Text] [Related]
13. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis.
Lin SM; Wang YM; Lin HC; Lee KY; Huang CD; Liu CY; Wang CH; Kuo HP
Crit Care Med; 2008 Mar; 36(3):683-9. PubMed ID: 18431261
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation.
Yasuda N; Goto K; Ohchi Y; Abe T; Koga H; Kitano T
J Crit Care; 2016 Dec; 36():29-34. PubMed ID: 27546744
[TBL] [Abstract][Full Text] [Related]
15. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
[TBL] [Abstract][Full Text] [Related]
16. Concomitant Versus Individual Administration of Antithrombin and Thrombomodulin for Sepsis-Induced Disseminated Intravascular Coagulation: A Nationwide Japanese Registry Study.
Umemura Y; Yamakawa K; Hayakawa M; Kudo D; Fujimi S
Clin Appl Thromb Hemost; 2018 Jul; 24(5):734-740. PubMed ID: 29471674
[TBL] [Abstract][Full Text] [Related]
17. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure.
Dhainaut JF; Shorr AF; Macias WL; Kollef MJ; Levi M; Reinhart K; Nelson DR
Crit Care Med; 2005 Feb; 33(2):341-8. PubMed ID: 15699837
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
Yamakawa K; Ogura H; Fujimi S; Morikawa M; Ogawa Y; Mohri T; Nakamori Y; Inoue Y; Kuwagata Y; Tanaka H; Hamasaki T; Shimazu T
Intensive Care Med; 2013 Apr; 39(4):644-52. PubMed ID: 23361628
[TBL] [Abstract][Full Text] [Related]
19. Impact of initial coagulation and fibrinolytic markers on mortality in patients with severe blunt trauma: a multicentre retrospective observational study.
Ishii K; Kinoshita T; Kiridume K; Watanabe A; Yamakawa K; Nakao S; Fujimi S; Matsuoka T
Scand J Trauma Resusc Emerg Med; 2019 Feb; 27(1):25. PubMed ID: 30819212
[TBL] [Abstract][Full Text] [Related]
20. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial.
Vincent JL; Francois B; Zabolotskikh I; Daga MK; Lascarrou JB; Kirov MY; Pettilä V; Wittebole X; Meziani F; Mercier E; Lobo SM; Barie PS; Crowther M; Esmon CT; Fareed J; Gando S; Gorelick KJ; Levi M; Mira JP; Opal SM; Parrillo J; Russell JA; Saito H; Tsuruta K; Sakai T; Fineberg D;
JAMA; 2019 May; 321(20):1993-2002. PubMed ID: 31104069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
